Company: ELV
Filing Date: 2025-09-08
Form Type: 424B3
Source: 0001193125-25-197796
Chunk: 83

Company: Elevance Health, Inc.
Filing Date: 2025-09-08
Form: 424B3
Chunk 83
---
 be given as to the liquidity of or trading market for any securities sold by us.

32

VALIDITY OF THE SECURITIES

In connection with particular offerings of the securities in the future, and if stated in the applicable prospectus supplements, the validity
of those securities may be passed upon for the Company by Hogan Lovells US LLP and Faegre Drinker Biddle & Reath LLP and for any underwriters or agents by counsel named in the applicable prospectus supplement. With respect to certain legal
matters relating to Indiana law, Hogan Lovells US LLP has relied upon the opinion of Faegre Drinker Biddle & Reath LLP, counsel for the Company.

EXPERTS

The consolidated financial statements and financial statement schedule for the year ended December 31, 2022 of Elevance Health appearing
in Elevance Health’s Exhibit 99.1 to the Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and the effectiveness of Elevance Health’s internal control over financial
reporting as of December 31, 2022 have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their reports thereon, included therein, and incorporated herein by reference. Such consolidated
financial statements and financial statement schedule are incorporated herein by reference in reliance upon such reports given on the authority of such firm as experts in accounting and auditing.

33

$

Elevance Health, Inc.

$ % Notes due 2028

$ % Notes due 2032

$ % Notes due 2036

$ % Notes due 2055

### PROSPECTUS SUPPLEMENT
, 2025

Joint Book-Running Managers

BofA Securities

Deutsche Bank Securities

Mizuho